It’s always nice to see left-leaning platforms call out the Democrats. It doesn’t happen often, but when it does, it puts a glorious smile on my face. We all know the Democrats lie, but my liberal friends, on the other hand, are convinced they could do no harm unless of course the MSM finally reports it.

The Hill just exposed the Democrats for falsely advertising drug pricing plans claiming that recent details show their proposal is more about raiding Medicare than it is about lowering their prescription drug costs.

On Friday morning The Hill reported that Democrats’ drug-pricing plan warrants a disinformation flag for seniors;

Senate Democrats are moving forward with a falsely advertised drug pricing plan. Liberals, and even maverick Sen. Joe Manchin (D-W.Va.), claim their newest plan will help lower drug costs for seniors and even drive down inflation. As always, however, the fine print says something else. In fact, the scheme would be a disaster for the development of life-extending, life-improving medicines, and medical devices.

Start with the money. The details show their proposal is more about raiding Medicare than it is about lowering their prescription drug costs. There is a $300 billion cut to the Medicare program, much of which would be immediately spent to extend expiring COVID-era emergency ObamaCare subsidies that went to higher-income earners.

According to The Hill, the Covid-era emergency ObamaCare subsidies really only helped insurance companies sell more ObamaCare policies to a bigger, newly eligible customer base, “but it certainly does not help lower seniors’ drug costs.”

The Hill went on to report, “as, for the supposed lower drug costs they claim seniors will benefit from, most of those would not materialize for at least three to five years — providing no immediate relief — until the drug pricing provisions have time to take effect.” Even beyond this irresponsible “spend now, save later” approach, seniors could find themselves subject to new access restrictions to certain medicines.

According to the Congressional Budget Office (CBO) and studies from the University of Chicago, patients and families will see fewer new cutting-edge treatments come about as private sector research and development investments dry up.

Democrats are also attempting to redefine “savings”. According to their new drug pricing plan, first, they would fully eliminate a significant Medicare reform that was approved by the Trump administration but has been purposely delayed by President Biden. Centered on negotiated rebates secured — and often kept — by pharmacy benefit managers (PBMs), the so-called rebate rule would have required big discounts on drugs to go directly to seniors enrolled in Medicare almost immediately, the Hill reported.

Furthermore, per the article, “these discounts would have been applied directly at the point of sale (i.e., local pharmacies, etc.) when individual seniors paid for their prescription medications. However, no new government programs or corporate middlemen would have been needed, so liberal Democrats naturally opposed it. Instead, Biden, House Speaker Nancy Pelosi (D-Calif.) and Senate Majority Leader Chuck Schumer (D-N.Y.) want a government-run program that identifies or “negotiates” potential savings so that they, not seniors, can collect the discounts and decide how to spend the money. That should not be a comforting prospect for seniors.”

Next, Democrats have falsely marketed their plan as a simple process by which the federal government will use its power to negotiate lower drug prices for Medicare beneficiaries. In reality, it is a price-control scheme no matter how it is advertised and will have the same devastating impacts price controls always do: diminished supply of the products in question. Worst, the creation of vital new drugs and treatments would whither. It typically costs $3 billion dollars and 15 years or so of development time to bring a drug to market.

In a way, the Democrat’s plan essentially sets a price and tells drug developers to take it or leave it, holding them hostage if they don’t accept Medicare’s offer, they could be subject to as much as a 95 percent excise tax on total sales of a particular medication.